Companies that succeed will need to prove their products save not only lives, but also money. Value-based approaches are already under way.
Learn how drug pricing model changes may affect the pharmaceutical industry.
The life sciences industry faces extra challenges in 3rd-party noncompliance. See how to identify high-risk areas and respond quickly.
When a life sciences/biotech company with a potentially lucrative new product in late-stage trials was looking for help with an IPO, they turned to Grant Thornton.
Creating customized sales strategies can help pharmaceutical companies succeed in a new landscape defined by the Affordable Care Act.
Innovation and perseverance are hallmarks of the life sciences industry. Rapidly evolving health care needs coupled with development of new markets present limitless opportunities in the industry. But even in a favorable environment, life sciences companies face challenges such as:
Principal, Advisory Services; National Life Sciences Sector Leader
Phone: +1 215 814 4000
Location: Philadelphia, PA
Principal, National Life Sciences Advisory Leader
Phone: +1 732 516 7669
Location: Iselin, NJ
Replay our webcast focusing on pharmaceutical pricing models that could soon be a reality, and how you should prepare.
The president has signed a sweeping tax and spending deal that will suspend the 2.3% medical device excise tax (MDET) for sales in 2016 and 2017.
Find CEO interviews, updates on recent legislation and articles on topics affecting your business.
See more at: http://www.grantthornton.com/industries/life-sciences